The pharmacokinetics and pharmacodynamics of the carbapenems: Focus on doripenem

Journal of Chemotherapy

Volumn 22, Issue 4, 2010, Pages 219-225

  Mazzei, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Carbapenem; Doripenem; Ertapenem; Imipenem; Meropenem

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CLARITHROMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DORIPENEM; ERTAPENEM; ERYTHROMYCIN; EXTENDED SPECTRUM BETA LACTAMASE; GLYCOPEPTIDE; IMIPENEM; KETOLIDE; MEROPENEM; METRONIDAZOLE; MONOBACTAM DERIVATIVE; OXAZOLIDINE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ABDOMINAL INFECTION; ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; BACTERICIDAL ACTIVITY; BACTEROIDES FRAGILIS; BLOODSTREAM INFECTION; CLINICAL TRIAL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PNEUMONIA; PREVOTELLA; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; ANIMAL;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; HUMANS;

EID: 78650242067     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2010.22.4.219     Document Type: Review

References (78)

1. Craig WA. Selecting the antibiotic. Proceedings of a Symposium. Sonoma 1993; 28 (Suppl 1): 26-27/1.
2. Craig WA, Gudmundsson S. Postantibiotic effect. In: Antibiotics in Lab oratory Medicine. (Lorian V, Ed). Williams and Wilkins, Baltimore, 1991: 403.
3. Craig WA. Post-antibiotic effects in experimental infection models; relationship to in vitro phenomenon and to treatment of infections in man. J Antimicrob Chemother 1993; 31 (Suppl D): 149-158. (Pubitemid 23193761)
4. Mazzei T. How Pharmacokinetic-Pharmacodynamic (PK-PD) Parameters Influence Antibiotic use. J Chemother 2006; 18(Cong. Rep.2): 19-21.
5. Owens RC-Jr, Ambrose P. Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era. Diagn Microbiol Infect Dis 2007; 57(3 Suppl): 77S-83S.
6. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007; 45(Suppl 1): S89-S95.
7. Mazzei T, Novelli A, Mini E, Periti P. Concentrazioni plasmatiche e tissutali degli antibiotici: quai è il loro valore predittivo? Ann Ital Medlnt 1992; 7(suppl 3): 67-73.
8. Rinaldi S, Novelli A, De Gaudio AR. Systemic antibiotics. In: Infection Control in Intensive Care Unit (van Saene HKF, Silvestri L, de la Cal, M.A. Eds.), Springer Verlag 2nd ed., 2005.
9. Czock D, Markert C, Hartman B, Keller F. Pharmacokinetics and pharmacodynamics of antimicrobial drugs. Expert Opin Drug Metab Toxicol 2009; 5(5): 475-487.
10. Andes D. Pharmacokinetics and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr OpinInfect Dis 2001; 14: 165-172. (Pubitemid 32232987)
11. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
12. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9(Suppl.3): 38-44. (Pubitemid 27294747)
13. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA 1998; 279: 125-129.
14. Moore RD, Lietman PS, Smith CR. Clinical response of aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155(1): 93-99. (Pubitemid 17225088)
15. Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB. Multicenter collaborative evaluation of standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987; 83(2): 218-222.
16. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081. (Pubitemid 23141323)
17. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998;20(5): 473-477.
18. Thomas JK, Forrest A, Bhavnani SM, Hyatt JM, Cheng A, Ballow CH, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-527. (Pubitemid 28114802)
19. Ambrose PG, Bhavnani SM, Owens RC-Jr. Clinical pharmacodynamics of quinolones. Infect DisClin North Am 2003;17(3): 529-543.
20. Schentag JJ, Gilliland KK, Paladino A. What we have learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32(Suppl. 1): 39-46.
21. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-259. (Pubitemid 26098477)
22. De Ryke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66(1): 1-14. (Pubitemid 43144960)
23. Roberts JA, Lipman J. Optimizing use of beta-lactam antibiotics in the critically ill. Semin Respir Crit Care Med 2007; 28(6): 579-585.
24. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37(3): 840-851.
25. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28(2): 143-160.
26. Dalhoff A et al., Biochemical Pharmacology, 2006
27. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenems. Drugs, 2007; 67(7): 1027-1052.
28. Shah PM. Parenteral carbapenems. Clin Microbiol Infect 2008; 14 (Suppl 1): 175-180.
29. Buckley MM, Brogden RN, Barradell LB, et al. Imipenem/cilastatin: a reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1992; 44(3): 408-444.
30. Norrby SR, Carbapenems. Med Clin North Am. 1995; 79(4): 745-759.
31. Moon YS, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis, 1997; 24(Suppl 2): S249-S255. (Pubitemid 27130714)
32. Zhanel GG, Simor AE, Vercaigne L, et al. Imipenem and meropenem comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis, 1998; 9(4): 215-228. (Pubitemid 28435078)
33. Majumdar AK, Musson DG, Birk KL, Zhang J, Hsieh JY, Fang W, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother, 2002; 46(11): 3506-3511.
34. Van Wart S, Bhavnani SM, Phillips L, Wikler MA, Ambrose PG. Population pharmacokinetics of doripenem [abstract no. A-18]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, Oct 30-Nov 2, 2004.
35. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9(1): 23-37.
36. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22.
37. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42: 2375-2379.
38. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am 1998; 12: 849-860. (Pubitemid 29004651)
39. Mouton JW, Punt N. Use of the t > MIC to choose between different dosing regimens of beta-lactam antibiotics. J Antimicrob Chemother 2001; 47: 500-501. (Pubitemid 32303426)
40. Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000; 39: 185-201.
41. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-1408. (Pubitemid 30327441)
42. Drusano GL. Antimicrobial pharmacodynamics - critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
43. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-268. (Pubitemid 34308974)
44. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosing regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
45. Dagan R, Klugman KP, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140.
46. Craig WA. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 1998; 77(Suppl. 6): S7-S11.
47. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-428.
48. Boselli E, Breilh D, Rimmele T, Poupelin JC, Saux MC, Chassard D, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004; 30: 989-991. (Pubitemid 38639498)
49. Williamson R, Tomasz A. Inhibition of cell wall synthesis and acylation of the penicillin binding proteins during prolonged exposure of growing Streptococcus pneumoniae to benzylpenicillin. Eur J Biochem 1985; 151: 475-483. (Pubitemid 16215779)
50. Drusano GL. Prevention of resistance: a goal for dose selection of antimicrobial agents. Clin Infect Dis 2003; 36(Suppl. 1): S42-S50. (Pubitemid 36140468)
51. Vondracek TG. Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 1995; 29: 415-424.
52. Scaglione F, Paraboni L. Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regiments. Int J Antimicrob Agents 2008; 32(4): 294-301.
53. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009; 64(1): 142-150.
54. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care unit). Antimicrob Agents Chemother 2002; 46(8): 2327-2332. (Pubitemid 34793431)
55. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous -infusion meropenem in adults with cystic fibrosis. Clin Ther 2004; 26: 493-501. (Pubitemid 38586450)
56. Psathas P, Kuzmission A, Ikeda K, Yasuo S. Stability of doripenem for injection (500 mg) in represantative infusion fluids and containers. Presented at the American Society of Hospital Pharmacists Summer Meeting; San Francisco; 22 July 2007.
57. Trissel LA, Brammer MK, Chan P, et al. Compatibility of doripenem injection wiLh selected other drugs during simulated y-site co-administration. Presented at the American Society of Hospital Pharmacists Midyear Meeting Las Vegas; 3 December 2007.
58. Lodise Jr TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-363. (Pubitemid 46147617)
59. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004; 26: 1187-1198. (Pubitemid 39445343)
60. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for β-lactams. Conn Med 2003; 67: 265-268. (Pubitemid 36622559)
61. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43: 1116-1123. (Pubitemid 37174443)
62. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health Syst Pharm 2004; 61: 1264-1270. (Pubitemid 39481462)
63. Kuti JL, Horea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii. and Pseudomonas aeruginosa. Pharmacotherapy 2004; 24: 8-15.
64. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients wiLh ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005; 49: 1337-1339. (Pubitemid 40463358)
65. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother 2005; 49: 461-463. (Pubitemid 40065834)
66. Dandekar PK, Maglio D, Sutherland CA, NighLingale CH, Nicolau DP. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 2003; 23: 988-991. (Pubitemid 36903999)
67. Sakka SG, Glauner AK, Bulitta JB, Kinzig-SChippers M, Pfisier W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51: 3304-3310. (Pubitemid 350067544)
68. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58: 916-929.
69. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005; 44(5): 539-549. (Pubitemid 40733738)
70. Kumar V, Burkhardt O, Pletz M, Welte T, Lode H, Derendorf H. Comparison of pharmacodynamic target attainment of ertapenem in healthy volunteers and intensive care unit patients using Monte Carlo simulations. AAPS J 2006; 8(Suppl. 2): 3378.
71. Burkhardt O, Kumar V, Katterwe D, Majcher-Peszynska J, Drewelow B, Derendorf H, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59: 277-284.
72. Brink AJ, Richards GA, Schillack V, Kiem S, SchenLag J. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int J Antimicrob Agents 2009; 33: 4332-4436.
73. th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Helsinki (Finland), May 16-19, 2009.
74. Vaccaro N, Umeh O, Redman R, Cirillo I. Pharmacokinetics of doripenem Ig administered over 4 hours in patients with ventilator-associated pneumonia [Poster no. A1-018]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 12-15 Sep, 2009.
75. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008; 9(1): 23-37.
76. Bhavnani SM, Hammel JP, Cirincione BB, Wikler MA, Ambrose PG. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support Phase II and III dosing strategies for doripenem. Antimicrob Agents Chemother 2005; 49(9): 3944-3947. (Pubitemid 41233056)
77. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic- pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 2009; 63(4): 409-414.
78. Cirillo I, Vaccaro N, Turner K, Bhavna S, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol 2009; 49: 798-806.